Summary
HLA evolutionary divergence reflects the ability to recognize diverse neoantigens as non-self, and as a biomarker is conceptually distinct from programmed cell death ligand 1 expression and tumor mutation burden. HLA-based assays to predict benefit from immunotherapy in lung cancer require prospective validation.
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.